Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors (ENERGY)
A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
BeiJing, Chine, 100020
- People's Liberation Army. The Military General Hospital of BeiJing
-
BeiJing, Chine, 100034
- Peiking University First Hospital
-
Beijing, Chine, 100853
- Chinese PLA General Hospital
-
Guangzhou, Chine, 510080
- The First Affiliated Hospital, Zhongshan (Sun Yat-sen) University
-
Guangzhou, Chine, 510120
- The Second Affiliated Hospital, Zhongshan (Sun Yat-sen) University
-
Guangzhou, Chine, 510515
- Nanfang Hospital, the Affiliated South Hospital of the Southern Medical University
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Newly diagnosed type 2 diabetes mellitus patients
- HbA1c > 6.5 and < 9.0%
- Fasting fingertip capillary blood glucose (FCBG) < 9 mmol/L after 2 weeks diet control
Exclusion Criteria:
- History of acute metabolic complications in the past 3 months or of severe diabetic complications or severe infections or active substance abuse
- Liver disease
- Patients under oral hypoglycemic drugs and/or insulin treatment, or corticosteroid treatment within past 4 weeks
Other protocol-defined inclusion/exclusion criteria applied to the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Nateglinide 120 mg
Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.
|
Nateglinide 120 mg was supplied as tablets.
Autres noms:
|
|
Comparateur actif: Acarbose 50 mg
Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.
|
Acarbose 50 mg was supplied as tablets.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. PPGE was defined as the mean difference between the preprandial glucose value and the postprandial glucose value measured at 2 hours in a standardized meal test.
Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
|
Baseline to the end of the study (Week 4)
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The peak postprandial glucose values were used in the calculation of change from Baseline at Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
|
Baseline to the end of the study (Week 4)
|
|
Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points.
Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
|
Baseline to the end of the study (Week 4)
|
|
Change From Baseline in Total Cholesterol at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of total cholesterol prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
Total cholesterol was assessed at each study site using the same method and same reference value.
|
Baseline to the end of the study (Week 4)
|
|
Change From Baseline in Triglycerides at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of triglycerides prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
Triglycerides were assessed at each study site using the same method and same reference value.
|
Baseline to the end of the study (Week 4)
|
|
Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of LDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
LDL-C was assessed at each study site using the same method and same reference value.
|
Baseline to the end of the study (Week 4)
|
|
Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
HDL-C was assessed at each study site using the same method and same reference value.
|
Baseline to the end of the study (Week 4)
|
|
Change From Baseline in Free Fatty Acids (FFA) at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of FFA prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
FFA was assayed at a central laboratory.
|
Baseline to the end of the study (Week 4)
|
|
Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of hsCRP prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. hsCRP was assayed at a central laboratory.
|
Baseline to the end of the study (Week 4)
|
|
Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4)
Délai: Baseline to the end of the study (Week 4)
|
Blood samples were collected for measurement of GSA prior to (fasting) the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
GSA was assayed at a central laboratory.
|
Baseline to the end of the study (Week 4)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Troubles du métabolisme du glucose
- Maladies métaboliques
- Maladies du système endocrinien
- Diabète sucré
- Diabète sucré, Type 2
- Agents hypoglycémiants
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Inhibiteurs de la glycoside hydrolase
- Acarbose
- Natéglinide
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- CDJN608ACN06
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .